Sandoz Inks $322M Deal for Biosimilars with Shanghai Henlius Biotech

Sandoz, a pharmaceutical company, has entered into a collaboration agreement with Shanghai Henlius Biotech to develop up to 10 biosimilars. The deal is worth up to $322 million and grants Sandoz ex-China rights to the biosimilars.

The initial assets included in the deal are copies of Amgen's Repatha (evolocumab), Eli Lilly's Erbitux (cetuximab), and GSK's Benlysta (belimumab). Sandoz also has an option on a recombinant human hyaluronidase called rHuPH20.

Henlius will handle development and manufacturing, leveraging its three manufacturing sites in China with a total capacity of 84,000 liters. European authorities have certified all the plants, while two facilities are good manufacturing practice-certified by U.S. regulatory agencies.